Score
2
2013
pubmed
[Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results].
Khavinson. V Kh VKh; Kuznik. B I BI; Ryzhak. G A GA
Key Findings
- Thymogen and other peptide bioregulators were reported to be safe in long‑term human use
- The authors claim these peptides can help prevent or slow age‑related diseases (geroprotection)
- Evidence comes from the authors’ own clinical studies across different age groups
Practical Outcomes
- For biohackers, the take‑away is that Thymogen is considered safe and potentially useful for immune support and anti‑aging, but the review lacks concrete dosage or regimen details. If you choose to try it, start with a low dose, track health markers, and treat it as an experimental supplement rather than a proven protocol.
Summary
The paper is a review of long‑term clinical work on several peptide bioregulators, including Thymogen, and suggests they might help prevent age‑related diseases and act as anti‑aging agents, but it doesn’t give new dosing rules or detailed protocols.
Abstract
The review summarizes the results of long-term studies of the authors on the clinical efficacy of peptide bioregulators (Timalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin, Retinalamin) for the prevention of diseases and treatment of people of different age. Special attention is given to the analysis of the use of peptide bioregulators as geroprotectors.
Study Information
Provider
pubmed
Year
2013